BGI Releases Pan-Cancer Early Screening Liquid Biopsy: One Blood Draw Screens 50 Cancers, 89% Early-Stage Accuracy

BGI releases revolutionary pan-cancer early screening liquid biopsy product. One blood draw can screen 50 common cancers. Early-stage (I-II) accuracy reaches 89%. Expected to popularize cancer screening to routine physical examinations.

BGI today released revolutionary pan-cancer early screening product — LunarGuard.

Technical Breakthrough

Cancer types screened: 50
Early-stage accuracy: 89% (Stage I-II)
False positive rate: <1%
Only 10ml blood needed

Pricing

Package price: 2,999 RMB
Annual screening version: 999 RMB/year

Market Significance

Previously cancer screening mostly targeted single cancer types at high prices. BGI lowered pan-cancer screening to within 3,000 RMB, expected to be included in routine physical examinations.

Clinical Data

100,000-person large-scale clinical trial shows LunarGuard's stage I-II cancer detection rate reaches 89%, late-stage (III-IV) detection rate exceeds 95%.

Disclaimer

Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.